News

– Second Quarter UDENYCA ®   Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million – REDWOOD CITY, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and

REDWOOD CITY, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020 .  “We are very pleased to welcome Kimberly Tzoumakas to our Board during this

REDWOOD CITY, Calif. , July 17, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 53,000 shares of

REDWOOD CITY, Calif. , July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 18, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 93,000 shares of

– First Quarter UDENYCA® Net Sales of $116.2 Million – –Net Income of $35.6 Million – – Non-GAAP Net Income of $49.8 Million – REDWOOD CITY, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported

REDWOOD CITY, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET .

REDWOOD CITY, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “notes”) in a private

REDWOOD CITY, Calif. , April 14, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026

COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 REDWOOD CITY, Calif. , April 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA ® and net income for the quarter ended

REDWOOD CITY, Calif. , March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of

REDWOOD CITY, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET , being held in Miami .

– US-based supply chain mitigates coronavirus-related disruption risks – – UDENYCA ® current inventory of over 300,000 syringes – REDWOOD CITY, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its United States

– Full Year UDENYCA ® Sales of $356.1 Million – – Full Year Cash Flow from Operating Activities of $28.4 million – REDWOOD CITY, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial

REDWOOD CITY, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40 th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET , being held in Boston .

REDWOOD CITY, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 18, 2020 , the compensation committee of the Company’s board of directors granted options to purchase 135,000 shares of the common

REDWOOD CITY, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020 . Starting at 4:30 p.m.

Agreement Includes an Option for Rituxan® Biosimilar REDWOOD CITY, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics , (Suzhou) Co., Ltd.,

REDWOOD CITY, Calif. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT , being held in San Francisco .